CLB

Core Laboratories (CLB): Q3 Non-GAAP EPS of $0.16 beats by $0.01; GAAP EPS of $0.07 misses by $0.07.Revenue of $105.38M (-39.2% Y/Y) misses by $3.95M.Shares +1% AH.Press Release

Core Laboratories (NYSE:CLB) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.15 by 6.67 percent. This is a 68 percent decrease over earnings of $0.50 per share from the same

Core Labs reports earnings on October 21st. Revenue is expected to fall by double digits amid demand destruction for oil.The company is rightsizing its cost structure, but cost take-outs may not fully offset declining scale in Q3.At just under 14x EBITDA, Core Labs appears fully valued. I rate the stock a Hold.

[[ALGN]], [[BCOV]], [[BDN]], [[CCI]], [[CLB]], [[CMG]], [[CNS]], [[CSX]], [[CVBF]], [[DFS]], [[EFX]], [[EW]], [[FR]], [[FTI]], [[GGG]], [[GL]], [[ICLR]], [[KALU]], [[KMI]], [[LRCX]], [[LSTR]], [[LVS]], [[MTH]], [[NTGR]], [[NWE]], [[SEIC]], [[SLG]], [[SLM]], [[STL]], [[SUI]],

Core Laboratories (NYSE:CLB) is scheduled to announce Q3 earnings results on Wednesday, October 21st, after market close.The consensus EPS Estimate is $0.15 and the consensus Revenue Estimate is $109.33M (-36.9% Y/Y).Over

On Wednesday, October 21, Core Laboratories (NYSE: CLB) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.What Are Earnings, Net Income, And Earnings Per Share (EPS)? Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.Earnings And Revenue Wall Street analysts see Core Laboratories reporting earnings of $0.16 per share on revenue of $114.04 million. In the same quarter last year, Core Laboratories reported EPS of $0.5 on revenue of $173.20 million.Why Analyst Estimates And Earnings Surprises Are Important Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a given company yields the "consensus estimates." If the company posts earnings or revenue above or below the consensus estimate, the stock may move by a considerable margin.View more earnings on CLBIf the company were to match the consensus estimate when it reports Wednesday, earnings would be down 68.0%. Revenue would be down 34.16% on a year-over-year basis. Core Laboratories's reported EPS has stacked up against analyst estimates in the past like this:Quarter Q2 2020 Q1 2020 Q4 2020 Q3 2019 EPS Estimate 0.10 0.35 0.37 0.49 EPS Actual 0.14 0.31 0.38 0.50 Revenue Estimate 115.35 M 153.86 M 156.04 M 171.79 M Revenue Actual 115.74 M 152.40 M 156.78 M 173.20 M Stock Performance Shares of Core Laboratories were trading at $14.84 as of October 19. Over the last 52-week period, shares are down 65.48%. Given that these returns are generally negative, long-term shareholders are probably down going into this earnings release.Do not be surprised to see the stock move on comments made during its conference call. Core Laboratories is scheduled to hold the call at 08:30:00 ET and can be accessed here: https://www.webcaster4.com/Webcast/Page/1000/37733See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Benzinga's Top Upgrades, Downgrades For September 29, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Core Laboratories' (CLB) Production Enhancement unit is expected to have incurred operating loss in Q3, same as the previous quarter.